CD69 and sarcoma: In addition, DFMO and GC7 treatment sustained CD69 expression in CD8+ T cells from human sarcoma tumor infiltrating lymphocytes (TIL) following activation with anti-CD3/CD28 and IL-2 (Supplemental Figure 4, A and F).